HIV / AIDS

July 10th 2025

This investigational two-drug regimen for treatment of adults with virologically suppressed HIV was given a Prescription Drug User Fee Act (PDUFA) date of April 28, 2026.

July 7th 2025

Grace Kulik, PT, DPT, discusses key risk factors and the role of inflammation, ART, and screening in preserving mobility among aging individuals with HIV.

June 27th 2025

6–3 ruling preserves no-cost insurance coverage for preventive services such as HIV PrEP, contraceptives, and screenings.

June 18th 2025

Gilead’s Yeztugo, a long-acting HIV capsid inhibitor, shows 96 to 100% efficacy in phase 3 trials and aims to expand access worldwide through regulatory filings and support programs.